GPS Wealth Strategies Group LLC Acquires New Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

GPS Wealth Strategies Group LLC bought a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 2nd quarter, Holdings Channel reports. The firm bought 465 shares of the company’s stock, valued at approximately $30,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Covestor Ltd lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 24.2% in the 1st quarter. Covestor Ltd now owns 955 shares of the company’s stock worth $62,000 after acquiring an additional 186 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new stake in Invesco Biotechnology & Genome ETF during the 4th quarter worth approximately $208,000. B. Riley Wealth Advisors Inc. acquired a new stake in Invesco Biotechnology & Genome ETF during the 1st quarter worth approximately $232,000. Cetera Advisors LLC acquired a new stake in Invesco Biotechnology & Genome ETF during the 1st quarter worth approximately $328,000. Finally, Banque Cantonale Vaudoise lifted its holdings in Invesco Biotechnology & Genome ETF by 39.0% during the 1st quarter. Banque Cantonale Vaudoise now owns 5,184 shares of the company’s stock worth $335,000 after buying an additional 1,454 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Up 1.9 %

Invesco Biotechnology & Genome ETF stock traded up $1.27 during mid-day trading on Thursday, reaching $69.91. 2,018 shares of the company’s stock were exchanged, compared to its average volume of 12,008. The company has a market cap of $282.44 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a twelve month low of $52.47 and a twelve month high of $71.19. The company has a fifty day moving average of $66.75 and a 200-day moving average of $64.89.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.